Reducing Risk for Thrombosis in Patients With Lung Cancer
Researchers have examined whether treatment with lazertinib-amivantamab entails an increased risk of venous thromboembolism in patients with advanced or metastatic non–small cell lung cancer.
Medscape Medical News
source https://www.medscape.com/viewarticle/993428?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/993428?src=rss
Comments
Post a Comment